{'fraction_non_alphanumeric': 0.02857142857142857, 'fraction_numerical': 0.010267857142857143, 'mean_word_length': 5.591176470588235, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Potential efficacy of a RNAi‐based topical treatment for psoriasis

Topical anti-psoriatic agents are the first choice for treating mild to moderate psoriasis, cases with contraindications for systemic immunosuppressive therapies, or for patients refusing systemic therapies (Eline, Van Gele, Grine, Remaut, & Lambert, in press). Most patients with psoriasis are not satisfied with the currently available topical agents in terms of efficacy, safety, patient adherence, and cost. Hence, introducing an effective anti-psoriatic topical with the least side effects would be optimal. Discovery of the molecular and genetic basis of psoriasis by microarray technology and Genome Wide Association Studies has resulted in molecular factors as targets for treating psoriasis. Today, theses targeted psoriasis therapies include antibody-based or fusion proteinbased biologic therapies such as T cell interfering agents, TNF-a antagonists, and anti-IL-17, IL-12, and IL-23 agents. RNA interference (RNAi) is a therapeutic gene silencing tool which can make pathology-causing genes silent. Delivery of this molecule in vivo has unfavorable physiochemical problems. Additionally, it is degraded by endogenous enzymes. For resolving this limitation, Eline developed an elastic liposomal formulation, called DDC642 as a topical delivery system for therapeutic RNAi molecules. They assessed the efficacy of DDC642-encapsulated RNAi molecules in treating psoriasis in vitro by three models: a standardized keratinocyte monolayer culture, psoriasis-induced keratinocytes, and a psoriasis reconstructed skin model. In this study, four genes, IL22RA1, KRT17, DEFB4, and TSLP which are upregulated in psoriasis lesions were selected as targets. The efficacy of a topical combined siRNA therapy was evaluated in the treatment of psoriasis. Eline et al. showed the effectiveness of DDC642-encapsulated RNAi molecules in gene silencing of each different target (except for the KRT17 expression), both at mRNA and protein level, and a reduced expression of specific psoriasis markers. It seems that combination of several siRNAs which target different key factors in the psoriasis pathogenesis can result in a synergistic effect on preventing disease progression.